Japanese CRO CAC EXICARE Teams with Medidata to Improve Customers’ Clinical Trial Efficiency and Effectiveness Through Cloud Technology

IT-Focused Japanese CRO Joins Medidata Partner Program to Meet Growing Asian Demand for Medidata Clinical Cloud

Japanese CRO CAC EXICARE Teams with Medidata to Improve Customers’ Clinical Trial Efficiency and Effectiveness Through Cloud Technology

EdelmanGeoff Curtis+1 312 233 1253orCAC EXICAREHiroshi WatanabeBTO Business Planning OfficeCorporate Planning Dept.+81 3 6667 8032

Japan-based contract research organization (CRO) has joined ’ (NASDAQ: MDSO) Partner Program to expand its services offerings to support the ™. As a new , CAC EXICARE is pursuing several across the Medidata cloud-based platform to support clinical trials in all phases, including Japanese post-marketing surveillance studies. Medidata’s innovative solutions for randomization and trial supply management (RTSM), electronic data capture and management, and medical coding will be supported by CAC EXICARE.

CAC EXICARE is a 2012 spinoff from CAC, an extensive IT services organization that has been supporting operations of pharmaceutical companies for more than 40 years. With deep expertise applying technology to bring efficiencies to its customer base of more than 150 life science companies, including Japanese branches of global pharmaceutical corporations, CAC EXICARE supports all phases of clinical development. At the request of many of their customers, CAC EXICARE decided to become a Medidata Services Partner and pursue accreditation in , the leading electronic data capture (EDC) and clinical data management (CDM) system, and is also pursuing accreditations in (for RTSM) and (for medical coding).

The nature of clinical research demands solutions that are globally accessible and still meet regulatory and security requirements. Medidata’s standards-based platform provides CAC EXICARE with a secure, collaborative environment that is configurable and flexible, —including easily integrating with other systems—accelerates study start-ups and enhances study execution.

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer implementation services for Medidata Rave. Since then, the Medidata Partner Program has grown to include 38 partners in the U.S., Europe and Asia, ranging from smaller clinical consultancies to large, global CROs. The program also now offers across the Medidata platform and supports partners with a variety of on-demand resources to help them optimize sponsors’ clinical trials.

is an IT systems integrator with rich experience and knowledge related to pharmaceutical R&D, as well as a CRO that provides contract services from clinical development to post-marketing surveillance. In April 2012, CAC Corporation split off its business unit of the clinical development operation and IT support services, and the new spinoff company started its business as CAC EXICARE Corporation. For more than past 40 years, we have been supporting operations of pharmaceutical companies by leveraging IT competence as our foundation.

is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Suggested Articles

Federal health centers across the country will receive nearly $107 million to support quality improvement efforts.

Planned Parenthood withdrew from the Title X program rather than comply with a new rule prohibiting providers from referring women for abortions.

While it continues to oppose “Medicare for All,” the American Medical Association has dropped out of a coalition organized to fight the proposal.